The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components

Apolipoprotein A-I (ApoA-I) amyloidosis is a rare protein misfolding disease where fibrils of the N-terminal domain of the protein accumulate in several organs, leading to their failure. Although ApoA-I amyloidosis is systemic, the different amyloidogenic variants show a preferential tissue accumulation that appears to correlate with the location of the mutation in the protein sequence and with the local extracellular microenvironment. However, the factors leading to cell/tissues damage, as well as the mechanisms behind the observed organ specificity are mostly unknown. Therefore, we investigated the impact of ApoA-I variants on cell physiology and the mechanisms driving the observed tissue specificity. We focused on four ApoA-I amyloidogenic variants and analyzed their cytotoxicity as well as their ability to alter redox homeostasis in cell lines from different tissues (liver, kidney, heart, skin). Moreover, variant-specific interactions with extracellular matrix (ECM) components were measured by synchrotron radiation circular dichroism and enzyme-linked immunosorbent assay. Data indicated that ApoA-I variants exerted a cytotoxic effect in a time and cell-type-specific manner that seems to be due to protein accumulation in lysosomes. Interestingly, the ApoA-I variants exhibited specific preferential binding to the ECM components, reflecting their tissue accumulation pattern in vivo. While the binding did not to appear to affect protein conformations in solution, extended incubation of the amyloidogenic variants in the presence of different ECM components resulted in different aggregation propensity and aggregation patterns.

[1]  M. Maiuri,et al.  Autophagy Alteration in ApoA-I Related Systemic Amyloidosis , 2022, International journal of molecular sciences.

[2]  D. Middleton,et al.  Raman spectroscopy with 2D perturbation correlation moving windows for the characterisation of heparin-amyloid interactions. , 2020, Analytical chemistry.

[3]  S. Ekström,et al.  Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux , 2020, bioRxiv.

[4]  L. Eliasson,et al.  Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[5]  J. Lagerstedt,et al.  High‐efficient bacterial production of human ApoA‐I amyloidogenic variants , 2018, Protein science : a publication of the Protein Society.

[6]  J. Straub,et al.  Molecular Insights into Human Hereditary Apolipoprotein A-I Amyloidosis Caused by the Glu34Lys Mutation. , 2018, Biochemistry.

[7]  N. Goto,et al.  Two novel APOA1 gene mutations in a Japanese renal transplant recipient with recurrent apolipoprotein A‐I related amyloidosis , 2018, Nephrology.

[8]  R. Piccoli,et al.  Cell milieu significantly affects the fate of AApoAI amyloidogenic variants: predestination or serendipity? , 2018, Biochimica et biophysica acta. General subjects.

[9]  D. Monti,et al.  Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[10]  Joan Domingo-Espín,et al.  Synchrotron radiation circular dichroism spectroscopy reveals structural divergences in HDL-bound apoA-I variants , 2017, Scientific Reports.

[11]  Shobini Jayaraman,et al.  Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis , 2017, Proceedings of the National Academy of Sciences.

[12]  C. Dobson,et al.  Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. , 2017, Annual review of biochemistry.

[13]  D. Middleton,et al.  Heparin and Methionine Oxidation Promote the Formation of Apolipoprotein A-I Amyloid Comprising α-Helical and β-Sheet Structures. , 2017, Biochemistry.

[14]  T. Rudd,et al.  High-throughput SRCD using multi-well plates and its applications , 2016, Scientific Reports.

[15]  H. Saito,et al.  Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes , 2016, Scientific Reports.

[16]  J. Nan,et al.  Heparin interactions with apoA1 and SAA in inflammation-associated HDL. , 2016, Biochemical and biophysical research communications.

[17]  S. Cushman,et al.  Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal , 2016, Diabetes.

[18]  G. Taylor,et al.  Amyloid cardiomyopathy associated with a novel apolipoprotein A–I Q172P variant , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[19]  S. Hung,et al.  Cellular Interaction and Cytotoxicity of the Iowa Mutation of Apolipoprotein A-I (ApoA-IIowa) Amyloid Mediated by Sulfate Moieties of Heparan Sulfate* , 2015, The Journal of Biological Chemistry.

[20]  Bill C. A. Pulford,et al.  CDApps: integrated software for experimental planning and data processing at beamline B23, Diamond Light Source , 2015, Journal of synchrotron radiation.

[21]  G. Siligardi,et al.  CD spectroscopy: an essential tool for quality control of protein folding. , 2015, Methods in molecular biology.

[22]  R. Falk,et al.  Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity , 2014, EMBO molecular medicine.

[23]  Shobini Jayaraman,et al.  Amyloidogenic mutations in human apolipoprotein A‐I are not necessarily destabilizing – a common mechanism of apolipoprotein A‐I misfolding in familial amyloidosis and atherosclerosis , 2014, The FEBS journal.

[24]  A. Schmidtchen,et al.  The Epidermal Growth Factor Receptor Is a Regulator of Epidermal Complement Component Expression and Complement Activation , 2014, The Journal of Immunology.

[25]  G. Hu,et al.  Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin , 2014, Cell Death and Disease.

[26]  M. Mörgelin,et al.  The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils , 2012, Journal of Lipid Research.

[27]  O. Gursky,et al.  The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. , 2012, Biochemistry.

[28]  T. Jávorfi,et al.  Circular dichroism beamline B23 at the Diamond Light Source. , 2012, Journal of Synchrotron Radiation.

[29]  D. Monti,et al.  Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells , 2011, Journal of cellular and molecular medicine.

[30]  P. Hawkins,et al.  Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. , 2011, The American journal of pathology.

[31]  N. Grigorieff,et al.  Nanoscale Flexibility Parameters of Alzheimer Amyloid Fibrils Determined by Electron Cryo-Microscopy** , 2010, Angewandte Chemie.

[32]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[33]  C. Röcken,et al.  Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. , 2009, The Journal of molecular diagnostics : JMD.

[34]  P. Hawkins,et al.  Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  R. Gallo,et al.  Glycosaminoglycans and their proteoglycans: host‐associated molecular patterns for initiation and modulation of inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Guido Franceschini,et al.  Structure, function and amyloidogenic propensity of apolipoprotein A-I , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[37]  E. Gruys,et al.  Glycosaminoglycans are part of amyloid fibrils: Ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[38]  J. Engler,et al.  Förster resonance energy transfer measurements are consistent with a helical bundle model for lipid-free apolipoprotein A-I. , 2005, Biochemistry.

[39]  E. Arbustini,et al.  Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. , 2004, Gastroenterology.

[40]  A. Beaudet,et al.  Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. , 2004, Gene.

[41]  J. Ávila,et al.  Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.

[42]  A. Olofsson,et al.  Only amyloidogenic intermediates of transthyretin induce apoptosis. , 2002, Biochemical and biophysical research communications.

[43]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[44]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.

[45]  M. Sunde,et al.  Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure , 2001, Protein science : a publication of the Protein Society.

[46]  D. Ostler,et al.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. , 2000, The American journal of pathology.

[47]  J. Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.

[48]  L. Ailles,et al.  Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. , 1992, Archives of pathology & laboratory medicine.

[49]  S. Prusiner,et al.  Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[50]  R. Gregg,et al.  A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. , 1990, Genomics.

[51]  S. Provencher,et al.  Estimation of globular protein secondary structure from circular dichroism. , 1981, Biochemistry.

[52]  B. Hazenberg Amyloidosis , 1933, The Indian medical gazette.